loxapine 🐢 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychoactive 1613 1977-10-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • loxapine
  • loxapin
  • oxilapine
  • loxapine succinate
  • cloxazepine
  • loxitane
  • adasuve
  • loxapine hydrochloride
  • loxapine HCl
  • loxipine maleate
An antipsychotic agent used in SCHIZOPHRENIA.
  • Molecular weight: 327.81
  • Formula: C18H18ClN3O
  • CLOGP: 3.68
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 28.07
  • ALOGS: -3.50
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
9.10 mg Inhal.powder
0.10 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.02 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 1975 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Poisoning deliberate 434.26 37.30 110 4396 11108 63473408
Coma 398.38 37.30 155 4351 64209 63420307
Neuroleptic malignant syndrome 244.12 37.30 71 4435 11985 63472531
Extrapyramidal disorder 182.23 37.30 58 4448 13226 63471290
Hepatocellular injury 144.68 37.30 59 4447 27322 63457194
Cholestasis 130.58 37.30 56 4450 29378 63455138
Oculogyric crisis 124.38 37.30 28 4478 1693 63482823
Intestinal obstruction 118.29 37.30 53 4453 30846 63453670
Somnolence 117.96 37.30 99 4407 178586 63305930
Altered state of consciousness 102.08 37.30 45 4461 25185 63459331
Toxicity to various agents 88.84 37.30 98 4408 247152 63237364
Hypothermia 84.68 37.30 33 4473 13548 63470968
Intentional overdose 84.36 37.30 57 4449 74095 63410421
Asphyxia 80.65 37.30 26 4480 6155 63478361
Catatonia 80.17 37.30 24 4482 4453 63480063
Miosis 76.21 37.30 26 4480 7327 63477189
Tachycardia 70.74 37.30 62 4444 118094 63366422
Benzodiazepine drug level increased 69.40 37.30 12 4494 180 63484336
Pneumonia aspiration 68.75 37.30 38 4468 34502 63450014
Cardio-respiratory arrest 67.95 37.30 46 4460 59913 63424603
Galactorrhoea 60.48 37.30 19 4487 4136 63480380
Hepatic cytolysis 57.55 37.30 26 4480 15381 63469135
Hyperprolactinaemia 57.46 37.30 18 4488 3882 63480634
Faecaloma 55.59 37.30 21 4485 7920 63476596
Brain death 55.56 37.30 17 4489 3393 63481123
Rhabdomyolysis 55.29 37.30 36 4470 43915 63440601
Hyperthermia 49.23 37.30 20 4486 9136 63475380
Antipsychotic drug level above therapeutic 49.15 37.30 12 4494 1031 63483485
Suicide attempt 49.04 37.30 38 4468 60880 63423636
Drug reaction with eosinophilia and systemic symptoms 48.24 37.30 30 4476 33806 63450710
Overdose 47.15 37.30 49 4457 115029 63369487
Sedation 46.89 37.30 31 4475 38778 63445738
Intestinal pseudo-obstruction 45.57 37.30 11 4495 901 63483615
Drug interaction 44.41 37.30 67 4439 229064 63255452
Dystonia 44.37 37.30 21 4485 13798 63470718
Hypotension 43.61 37.30 73 4433 272531 63211985
Urinary retention 43.53 37.30 27 4479 30274 63454242
Cardiogenic shock 42.02 37.30 22 4484 17910 63466606
Poisoning 41.49 37.30 20 4486 13680 63470836
Wrong patient received product 40.24 37.30 12 4494 2195 63482321
Myocarditis septic 39.65 37.30 6 4500 36 63484480
Amenorrhoea 37.87 37.30 17 4489 9897 63474619

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 387.57 38.28 189 7096 45489 34904157
Antipsychotic drug level below therapeutic 373.07 38.28 90 7195 2457 34947189
Therapeutic product effect variable 360.83 38.28 87 7198 2369 34947277
Disinhibition 356.86 38.28 91 7194 3135 34946511
Akathisia 331.00 38.28 105 7180 8004 34941642
Obsessive-compulsive disorder 329.75 38.28 96 7189 5468 34944178
Euphoric mood 302.14 38.28 90 7195 5551 34944095
Increased appetite 277.73 38.28 90 7195 7339 34942307
Poisoning deliberate 191.19 38.28 69 7216 7775 34941871
Suicide attempt 185.12 38.28 110 7175 39006 34910640
Neuroleptic malignant syndrome 172.31 38.28 81 7204 17853 34931793
Leukaemia 137.02 38.28 47 7238 4556 34945090
Therapeutic product effect incomplete 133.90 38.28 99 7186 50442 34899204
Extrapyramidal disorder 126.22 38.28 59 7226 12821 34936825
Hepatocellular injury 125.06 38.28 70 7215 22141 34927505
Wrong patient received product 123.38 38.28 38 7247 2616 34947030
Dyslipidaemia 114.74 38.28 47 7238 7441 34942205
Leukopenia 112.81 38.28 98 7187 62758 34886888
Rhabdomyolysis 111.84 38.28 101 7184 68062 34881584
Obesity 102.02 38.28 51 7234 12827 34936819
Prescribed overdose 98.86 38.28 47 7238 10600 34939046
Hypothermia 98.43 38.28 47 7238 10701 34938945
Miosis 94.40 38.28 44 7241 9491 34940155
Weight increased 92.27 38.28 105 7180 92928 34856718
Intestinal obstruction 92.01 38.28 58 7227 22764 34926882
Product use in unapproved indication 84.84 38.28 113 7172 117386 34832260
Toxicity to various agents 83.10 38.28 149 7136 200213 34749433
Somnolence 81.96 38.28 108 7177 111008 34838638
Faecaloma 76.45 38.28 32 7253 5345 34944301
Hyperleukocytosis 61.74 38.28 21 7264 1981 34947665
Fatigue 58.92 38.28 5 7280 370648 34578998
Colitis ischaemic 58.31 38.28 28 7257 6447 34943199
Pneumonia aspiration 53.26 38.28 54 7231 41849 34907797
Subileus 52.12 38.28 21 7264 3182 34946464
Schizoaffective disorder 49.22 38.28 16 7269 1311 34948335
Choking 49.18 38.28 23 7262 4992 34944654
Psychotic symptom 48.76 38.28 17 7268 1726 34947920
Congestive cardiomyopathy 48.67 38.28 26 7259 7484 34942162
Necrotising colitis 48.12 38.28 15 7270 1073 34948573
Electrocardiogram QT prolonged 45.29 38.28 49 7236 40903 34908743
Hyperthermia 42.89 38.28 27 7258 10550 34939096
Tachycardia 42.86 38.28 69 7216 84703 34864943
Bradypnoea 40.76 38.28 17 7268 2812 34946834
Blood creatine phosphokinase increased 39.98 38.28 48 7237 44809 34904837
Bladder dilatation 39.63 38.28 14 7271 1478 34948168
Diarrhoea 39.55 38.28 16 7269 389896 34559750
Cardio-respiratory arrest 39.53 38.28 53 7232 55220 34894426

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 794.55 33.35 344 10162 100305 79633577
Poisoning deliberate 599.50 33.35 181 10325 18647 79715235
Neuroleptic malignant syndrome 397.95 33.35 146 10360 27413 79706469
Extrapyramidal disorder 315.72 33.35 117 10389 22562 79711320
Hepatocellular injury 265.06 33.35 128 10378 47465 79686417
Somnolence 213.89 33.35 206 10300 238775 79495107
Rhabdomyolysis 191.59 33.35 136 10370 102995 79630887
Intestinal obstruction 187.39 33.35 98 10408 42922 79690960
Hypothermia 186.04 33.35 80 10426 22666 79711216
Miosis 178.43 33.35 70 10436 15719 79718163
Wrong patient received product 166.77 33.35 49 10457 4569 79729313
Faecaloma 136.76 33.35 53 10453 11511 79722371
Akathisia 136.61 33.35 55 10451 13204 79720678
Pneumonia aspiration 132.84 33.35 92 10414 66875 79667007
Altered state of consciousness 120.76 33.35 74 10432 43748 79690134
Catatonia 110.22 33.35 42 10464 8714 79725168
Tachycardia 106.57 33.35 124 10382 177644 79556238
Antipsychotic drug level below therapeutic 101.00 33.35 25 10481 1213 79732669
Asphyxia 98.36 33.35 42 10464 11678 79722204
Cardio-respiratory arrest 97.63 33.35 94 10412 108416 79625466
Hyperthermia 95.75 33.35 47 10459 17990 79715892
Cholestasis 92.68 33.35 67 10439 52042 79681840
Suicide attempt 90.43 33.35 80 10426 82852 79651030
Toxicity to various agents 90.33 33.35 182 10324 421358 79312524
Therapeutic product effect variable 89.00 33.35 25 10481 1984 79731898
Fatigue 88.04 33.35 10 10496 929717 78804165
Oculogyric crisis 87.91 33.35 27 10479 2925 79730957
Choking 87.35 33.35 39 10467 12062 79721820
Disinhibition 86.96 33.35 26 10480 2572 79731310
Subileus 85.37 33.35 31 10475 5623 79728259
Hyperleukocytosis 82.53 33.35 25 10481 2585 79731297
Necrotising colitis 79.82 33.35 20 10486 1020 79732862
Congestive cardiomyopathy 75.66 33.35 35 10471 11745 79722137
Bladder dilatation 74.38 33.35 22 10484 2097 79731785
Hepatic cytolysis 72.61 33.35 45 10461 27106 79706776
Drug abuse 66.65 33.35 94 10412 162597 79571285
Blood creatine phosphokinase increased 66.59 33.35 61 10445 66029 79667853
Euphoric mood 62.56 33.35 27 10479 7699 79726183
Electrocardiogram QT prolonged 62.53 33.35 68 10438 90318 79643564
Obsessive-compulsive disorder 62.47 33.35 25 10481 5902 79727980
Benzodiazepine drug level increased 59.51 33.35 12 10494 224 79733658
Intentional overdose 58.60 33.35 71 10435 105889 79627993
Pain 58.59 33.35 11 10495 703791 79030091
Bradypnoea 58.53 33.35 24 10482 6028 79727854
Drug interaction 58.50 33.35 152 10354 415031 79318851
Urinary retention 58.47 33.35 53 10453 56577 79677305
Sedation 56.41 33.35 50 10456 51845 79682037
Poisoning 55.48 33.35 37 10469 25235 79708647
Agitation 52.20 33.35 65 10441 99650 79634232
Dyslipidaemia 52.02 33.35 27 10479 11606 79722276
Galactorrhoea 51.37 33.35 19 10487 3627 79730255
Product use in unapproved indication 50.99 33.35 106 10400 250253 79483629
Drug reaction with eosinophilia and systemic symptoms 50.96 33.35 52 10454 64192 79669690
Respiratory acidosis 50.10 33.35 26 10480 11174 79722708
Distal intestinal obstruction syndrome 49.92 33.35 13 10493 774 79733108
Faecal vomiting 49.84 33.35 14 10492 1110 79732772
Colitis ischaemic 47.62 33.35 28 10478 15331 79718551
Arthralgia 47.42 33.35 9 10497 571794 79162088
Wrong product administered 46.38 33.35 23 10483 8989 79724893
Intestinal ischaemia 45.96 33.35 26 10480 13244 79720638
Housebound 45.91 33.35 11 10495 465 79733417
Increased appetite 45.67 33.35 25 10481 11953 79721929
Psychotic symptom 45.28 33.35 16 10490 2681 79731201
Dystonia 43.80 33.35 30 10476 21369 79712513
Brain death 43.23 33.35 19 10487 5658 79728224
Aggression 41.78 33.35 42 10464 50916 79682966
Salivary hypersecretion 41.67 33.35 25 10481 14199 79719683
Antipsychotic drug level above therapeutic 41.35 33.35 14 10492 2066 79731816
Psychotic disorder 41.27 33.35 38 10468 41364 79692518
Confusional state 41.26 33.35 113 10393 317884 79415998
Diarrhoea 40.60 33.35 34 10472 880455 78853427
Nausea 40.53 33.35 40 10466 957156 78776726
Hyperprolactinaemia 40.03 33.35 17 10489 4659 79729223
Dyspnoea 39.62 33.35 33 10473 856992 78876890
Dyskinesia 38.74 33.35 38 10468 44735 79689147
Parkinsonism 38.14 33.35 25 10481 16559 79717323
Headache 37.14 33.35 20 10486 653752 79080130
Schizoaffective disorder 37.02 33.35 13 10493 2139 79731743
Rash 37.00 33.35 15 10491 578343 79155539
Myocarditis septic 35.94 33.35 6 10500 36 79733846
Diabetic hyperosmolar coma 35.67 33.35 10 10496 787 79733095
Camptocormia 35.54 33.35 9 10497 479 79733403
Psychomotor skills impaired 35.00 33.35 16 10490 5221 79728661
Drug resistance 34.99 33.35 35 10471 42178 79691704
Hypometabolism 34.69 33.35 7 10499 131 79733751
Obesity 34.54 33.35 32 10474 35093 79698789
Compensatory sweating 34.43 33.35 6 10500 48 79733834

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AH01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Diazepines, oxazepines, thiazepines and oxepines
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35476 neuroleptics
CHEBI has role CHEBI:48561 dopaminergic antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bipolar disorder indication 13746004 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Alcoholism contraindication 7200002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Glaucoma contraindication 23986001 DOID:1686
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Coma contraindication 371632003
Carcinoma of female breast contraindication 447782002
Pigmentary Retinopathy contraindication
Drug Induced CNS Depression contraindication




🐢 Veterinary Drug Use

None

🐢 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.59 Basic
pKa2 3.24 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.62 CHEMBL CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 7.68 CHEMBL CHEMBL
D(1A) dopamine receptor GPCR Ki 7.27 PDSP
Alpha-2A adrenergic receptor GPCR Ki 6.82 PDSP
Sodium-dependent noradrenaline transporter Transporter Ki 5.24 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 5.61 PDSP
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8 IUPHAR
5-hydroxytryptamine receptor 6 GPCR Ki 7.82 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.51 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.97 PDSP
D(3) dopamine receptor GPCR ANTAGONIST IC50 7.66 CHEMBL
D(1B) dopamine receptor GPCR Ki 7.13 PDSP
Histamine H1 receptor GPCR ANTAGONIST Ki 8.20 IUPHAR
Histamine H2 receptor GPCR Ki 6.68 PDSP
Histamine H4 receptor GPCR Ki 5.30 PDSP
Muscarinic acetylcholine receptor M1 GPCR IC50 5.26 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 6.38 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 6.91 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 6.09 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 6.83 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 6.41 PDSP
D(4) dopamine receptor GPCR ANTAGONIST Ki 8.31 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel Ki 6.72 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.28 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.11 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.85 PDSP
Potassium channel subfamily K member 2 Ion channel IC50 4.70 CHEMBL
Potassium channel subfamily T member 1 Ion channel ACTIVATOR EC50 5.36 IUPHAR
Alpha-2C adrenergic receptor GPCR Ki 7.10 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 5.46 PDSP
D(2) dopamine receptor GPCR Ki 7.68 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 8.22 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.37 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 6 CHEMBL
Histamine H1 receptor GPCR IC50 6 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.80 IUPHAR
Adrenergic receptor alpha-1 GPCR IC50 7.74 CHEMBL

External reference:

IDSource
4019805 VUID
N0000147894 NUI
D00794 KEGG_DRUG
27833-64-3 SECONDARY_CAS_RN
4017917 VANDF
4017918 VANDF
4019805 VANDF
C0024056 UMLSCUI
CHEBI:50841 CHEBI
CHEMBL831 ChEMBL_ID
CHEMBL1201155 ChEMBL_ID
DB00408 DRUGBANK_ID
D008152 MESH_DESCRIPTOR_UI
3964 PUBCHEM_CID
205 IUPHAR_LIGAND_ID
2610 INN_ID
54810-23-0 SECONDARY_CAS_RN
LER583670J UNII
1364415 RXNORM
1308 MMSL
1346 MMSL
196711 MMSL
29026 MMSL
4999 MMSL
5000 MMSL
d00897 MMSL
001522 NDDF
001523 NDDF
001524 NDDF
1971003 SNOMEDCT_US
30745005 SNOMEDCT_US
372789006 SNOMEDCT_US
59270007 SNOMEDCT_US
CHEMBL1201060 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1394 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1394 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1395 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1395 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1396 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1396 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1397 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1397 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0369 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0370 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0371 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0372 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-585 TABLET 5 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-586 TABLET 10 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-587 TABLET 25 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-588 TABLET 50 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 17856-1397 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 35573-436 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 35573-437 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 35573-438 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 35573-439 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4701 CAPSULE 10 mg ORAL ANDA 21 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4701 CAPSULE 10 mg ORAL ANDA 21 sections
Adasuve HUMAN PRESCRIPTION DRUG LABEL 1 51097-001 AEROSOL, POWDER 10 mg RESPIRATORY (INHALATION) NDA 31 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 62135-492 CAPSULE 5 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 62135-493 CAPSULE 10 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-890 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-890 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-891 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-891 CAPSULE 10 mg ORAL ANDA 20 sections